RxDoctor Payments Data

Nghia Truong, MD

Internal Medicine · Tyler, TXNPI 1407876626

Payments from drug & device makers

$8,383in general payments, 2019–2025

Across 546 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$1K
  • Novartis$671
  • Pfizer$665
  • GSK$582
  • Sumitomo Pharma America, Inc.$567
  • plus $4K from 33 others

What the payments were for

  • Food & beverage$8,383100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,383 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$485,146
Medicare patients
935
Services billed
6,272

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin253$251,525
EliquisApixaban197$209,220
OzempicSemaglutide187$201,720
MounjaroTirzepatide151$166,069
TrulicityDulaglutide73$102,369
XareltoRivaroxaban118$84,160
JanuviaSitagliptin Phosphate69$65,382
CreonLipase/Protease/Amylase29$50,317
JanumetSitagliptin Phos/Metformin Hcl46$47,292
TradjentaLinagliptin60$45,081
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$40,245
Repatha SureclickEvolocumab47$38,242
MyrbetriqMirabegron62$36,119
ZenpepLipase/Protease/Amylase24$29,425
LinzessLinaclotide26$26,070

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$89$305,365331 claims
Lilly USA, LLCMounjaro, Trulicity$543$268,438224 claims
PfizerEliquis$665$209,220197 claims
Novo NordiskOzempic$1,119$201,720187 claims
MerckJanuvia, Janumet$58$112,674115 claims
Johnson & JohnsonXarelto$86$84,160118 claims
AbbVieCreon, Linzess, Synthroid$1,277$83,941170 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$582$58,577101 claims
Astellas Pharma US IncMyrbetriq$267$36,11962 claims
AstraZenecaFarxiga, Breztri Aerosphere$426$29,16234 claims
NovartisEntresto$671$9,46516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →